A detailed history of Rubric Capital Management LP transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Rubric Capital Management LP holds 10,400,000 shares of CHRS stock, worth $15.8 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
10,400,000
Previous 10,400,000 -0.0%
Holding current value
$15.8 Million
Previous $18 Million 39.88%
% of portfolio
0.3%
Previous 0.53%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.02 - $3.14 $20.2 Million - $31.4 Million
10,004,793 Added 2531.53%
10,400,000 $24.9 Million
Q4 2023

Feb 13, 2024

BUY
$1.59 - $3.85 $628,379 - $1.52 Million
395,207 New
395,207 $1.32 Million
Q2 2020

Aug 10, 2020

SELL
$14.43 - $19.16 $22.8 Million - $30.3 Million
-1,583,061 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$11.67 - $22.53 $6.34 Million - $12.2 Million
-543,019 Reduced 25.54%
1,583,061 $25.7 Million
Q4 2019

Feb 14, 2020

BUY
$16.33 - $21.37 $1.45 Million - $1.89 Million
88,550 Added 4.35%
2,126,080 $38.3 Million
Q3 2019

Nov 14, 2019

BUY
$16.3 - $23.37 $21.8 Million - $31.3 Million
1,337,530 Added 191.08%
2,037,530 $41.3 Million
Q2 2019

Aug 13, 2019

SELL
$13.1 - $22.1 $25.4 Million - $42.9 Million
-1,940,771 Reduced 73.49%
700,000 $15.5 Million
Q1 2019

May 10, 2019

SELL
$8.38 - $15.5 $3.43 Million - $6.34 Million
-409,229 Reduced 13.42%
2,640,771 $36 Million
Q4 2018

Feb 13, 2019

BUY
$8.65 - $16.28 $20.9 Million - $39.4 Million
2,420,000 Added 384.13%
3,050,000 $27.6 Million
Q3 2018

Nov 13, 2018

BUY
$14.45 - $20.25 $4.17 Million - $5.84 Million
288,510 Added 84.49%
630,000 $10.4 Million
Q2 2018

Aug 14, 2018

SELL
$10.25 - $17.45 $1.25 Million - $2.13 Million
-121,906 Reduced 26.31%
341,490 $4.78 Million
Q1 2018

May 14, 2018

BUY
$9.1 - $13.7 $4.22 Million - $6.35 Million
463,396 New
463,396 $5.12 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $118M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.